

**FAX TRANSMITTAL**  
**TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
DEAV2003/0008 US NP

Applicants:  
MICHAELIS, et al

Serial No.  
10/773,772

Filing Date:  
02/06/2004

Title of Invention:  
**THE USE OF ANTAGONISTS OF THE BRADYKININ B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHRISIS**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703-872-9306, on

Date of Deposit August 31, 2004

Printed Name of Person Signing Certificate Paul Irvine

Signature

Total Number of Pages Sent: 7

Agent: Jiang Lin

Group Art Unit: 1646

Examiner: Not Yet Known

TO: Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal   |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____   |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <b><u>REQUEST FOR CORRECTED FILING RECEIPT</u></b> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <b><u>Copy of Filing Receipt</u></b>               |
| <input type="checkbox"/> Maintenance Fee Transmittal           | <input checked="" type="checkbox"/> Other <b><u>Copy of the Application Data Sheet</u></b>   |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)